

IN THE CLAIMS

In this Response, claim 38 has been amended. Claims 32-37, 39, and 44-64 have been canceled.

Claims 1-31 (canceled)

Claims 32-37 (canceled)

38. (currently amended) A stent, comprising:

a body having a first end and a second end and a middle segment between the first and second ends; and

a plurality of polymeric strips circumferentially spaced from each other around the body of the stent, wherein the plurality of polymeric strips are disposed at or adjacent to the first and/or second end of the stent and do not extend into the middle segment of the body.

39. (canceled)

40. (previously presented) The stent of Claim 38, wherein the plurality of polymeric strips include a drug.

41. (previously presented) The stent of Claim 38, wherein the plurality of polymeric strips include a bioabsorbable material.

42. (previously presented) The stent of Claim 41, wherein the bioabsorbable material is selected from the group consisting of hyaluronic acid, water soluble chondroitin sulfate, poly(ethylene glycol), poly(vinyl pyrrolidone), poly(caprolactone-co-ethylene glycol), poly(lactic acid-co-ethylene glycol), polybutylene terephthalate and poly alpha-hydroxy acids.

43. (previously presented) The stent of Claim 40, wherein the drug is selected from the group consisting of anti-proliferative drugs, anti-platelet drugs, TB3A inhibitors and nitric oxide donors.

Claims 44-64 (canceled)